Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,644.80up ₹17.30 (1.06%)BSE ₹1,640.10
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,627.50.
28 Oct: open ₹1,625.00, high ₹1,650.00, low ₹1,609.10
52-week range of traded prices to 28 Oct 2026
₹1,081.40Low, 28 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹94,638 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.49
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.50
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 5,54,485
Aurobindo Pharma has 1,689 announcements on record, routine notices left out; 8 in the 30 days to 28 Oct 2026, the latest on 26 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Aurobindo Pharma quarterly results
Nov4Wed
The board meets on 4 Nov 2026 to consider financial results and dividend
Notice filed 26 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026 and dividend
Aurobindo Pharma annual reports, presentations and earnings calls
The company's own documents, latest first.Aurobindo Pharma financials, year by year
Annual reports17
- Annual report, year to Mar 20263 Aug 2026
- Annual report, year to Mar 202514 Aug 2025
- Annual report, year to Mar 20245 Aug 2024
- Annual report, year to Mar 20231 Aug 2023, a zip file
- Annual report, year to Mar 20229 Jul 2022, a zip file
12 earlier reports
- Annual report, year to Mar 20214 Aug 2021, a zip file
- Annual report, year to Mar 20204 Aug 2020, a zip file
- Annual report, year to Mar 20195 Aug 2019, a zip file
- Annual report, year to Mar 20184 Sep 2018, a zip file
- Annual report, year to Mar 20174 Sep 2017, a zip file
- Annual report, year to Mar 201629 Aug 2016, a zip file
- Annual report, year to Mar 20153 Aug 2015, a zip file
- Annual report, year to Mar 20141 Aug 2014, a zip file
- Annual report, year to Mar 201315 Jul 2013, a zip file
- Annual report, year to Mar 201220 Jul 2012, a zip file
- Annual report, year to Mar 201111 May 2012, a zip file
- Annual report, year to Mar 20108 Sep 2010, a zip file
Investor presentations57
- Investor Presentation5 Aug 2026
- Investor Presentation21 May 2026
- Investor Presentation10 Feb 2026
- Investor Presentation9 Feb 2026
- Investor Presentation5 Nov 2025
52 earlier presentations
- Investor Presentation4 Aug 2025
- Investor Presentation26 May 2025
- Investor Presentation6 Feb 2025
- Earnings Presentation9 Nov 2024
- Investor Presentation10 Aug 2024
- Investor Presentation25 May 2024
- Investor Presentation13 Mar 2024
- Investor Presentation10 Feb 2024
- Investor Presentation9 Nov 2023
- Investor Presentation27 May 2023
- Investor Presentation9 Feb 2023
- Please refer to our letter dated November 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on November 14, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Second quarter and half year ended September 30, 2022.The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/12 Nov 2022
- Further to our letter dated September 6, 2022 informing about the participation in the Kotak Institutional Equity Healthcare Forum 2022 on September 8, 2022, we inform you that the presentation updated in the following weblink of the Company will be used during the interaction with the investors.https://www.aurobindo.com/wp-content/uploads/2022/09/Aurobindo-Pharma_Investor-Presentation_INR_Sep-22.pdfNo unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.7 Sep 2022
- Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2022. The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/11 Aug 2022
- Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022. The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/30 May 2022
- Investor Presentation9 Feb 2022
- Investor Presentation8 Nov 2021
- Investor Presentation12 Aug 2021
- Investor Presentation31 May 2021
- Investor Presentation10 Feb 2021
- Investor Presentation11 Nov 2020
- Investor Presentation12 Aug 2020
- Investor Presentation3 Jun 2020
- Investor Presentation6 Feb 2020
- Investor Presentation12 Nov 2019
- Investor Presentation7 Aug 2019
- Investor Presentation28 May 2019
- Investor Presentation7 Feb 2019
- Investor Presentation12 Nov 2018
- Investor Presentation9 Aug 2018, a zip file
- Investor Presentation28 May 2018, a zip file
- Investor Presentation7 Feb 2018, a zip file
- Investor Presentation8 Jan 2018, a zip file
- Investor Presentation16 Nov 2017, a zip file
- Investor Presentation9 Nov 2017, a zip file
- Investor Presentation9 Aug 2017, a zip file
- Investor Presentation26 Jun 2017, a zip file
- Investor Presentation14 Jun 2017, a zip file
- Investor Presentation1 Jun 2017, a zip file
- Investor Presentation29 May 2017, a zip file
- Investor Presentation24 Mar 2017, a zip file
- Investor Presentation22 Feb 2017, a zip file
- Investor Presentation13 Feb 2017, a zip file
- Investor Presentation9 Feb 2017, a zip file
- Investor Presentation9 Jan 2017, a zip file
- Investor Presentation15 Nov 2016, a zip file
- Investor Presentation14 Nov 2016, a zip file
- Presentation to the Investors / Analysts.14 Sep 2016, a zip file
- Presentation to the Investors / Analysts.7 Sep 2016, a zip file
- Presentation to the Investors / Analysts.29 Aug 2016, a zip file
- Investors/Analysts Presentation23 Aug 2016, a zip file
- Investor Presentation made at "JP Morgan Global Healthcare Conference, San Francisco, USA" on January 12, 2016 at 2.00 p.m. (San Francisco time) (13th January 2016 at 3.30 am IST) is available on company's website at the following URL: http://www.aurobindo.com/docs/annual-reports/aurobindo-pharma-ltd-jp-morgan-healthcare-conference-investor-presentation-jan-2016.pdf13 Jan 2016, a zip file
Earnings calls31
- Transcript13 Aug 2026
- Transcript27 May 2026
- Transcript16 Feb 2026
- Transcript11 Nov 2025
- Transcript8 Aug 2025
26 earlier call documents
- Transcript2 Jun 2025
- Transcript13 Feb 2025
- Transcript18 Nov 2024
- Link of Recording11 Nov 2024
- Transcript16 Aug 2024
- Link of Recording12 Aug 2024
- Transcript31 May 2024
- Link of Recording27 May 2024
- Transcript16 Feb 2024
- Link of Recording12 Feb 2024
- Transcript15 Nov 2023
- Link of Recording10 Nov 2023
- Transcript18 Aug 2023
- Link of Recording14 Aug 2023
- Please refer to our letter dated May 19, 2023, wherein we intimated about the schedule of Investors/ Analysts call on May 29, 2023. We are attaching herewith the Transcript of the said analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023, and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-call-transcripts/1 Jun 2023
- Link of Recording29 May 2023
- Transcript17 Feb 2023
- And further to our letter dated February 3, 2023, please note that the audio recording of the earnings call on the unaudited financial results for the third quarter and nine months period ended December 31, 2022, held on February 10, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/10 Feb 2023
- Sub: Transcript of Q2FY23 earnings call.Please refer to our letter dated November 8, 2022 wherein we intimated about the schedule of Investors/Analysts call on November 14, 2022. We are attaching herewith the Transcript of the said analyst / investorcall on the Unaudited Financial Results of the Company for the second quarter and half year endedSeptember 30, 2022 and the same is being uploaded on the website of the Company and is available in thefollowing web link.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-calltranscripts/Please take the information on record.18 Nov 2022
- And further to our letter dated November 8, 2022, please note that the audio recording of the earnings call on the unaudited financial results for the second quarter and half year ended September 30, 2022, held on November 14, 2022, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/14 Nov 2022
- Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/19 Aug 2022
- Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/6 Jun 2022
- And further to our letter dated May 26, 2022, please note that the audio recording of the earnings call for the fourth quarter and financial year ended March 31, 2022, held on May 31, 2022, at 8.30 AM (IST) has been uploaded on our website on the following web-link:https://www.aurobindo.com/wp-content/uploads/2022/05/Aurobindo-Q4-.mp331 May 2022
- Transcript17 Feb 2022
- Transcript19 Nov 2021
- Transcript of earnings call.2 Sep 2016, a zip file
Aurobindo Pharma merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings11
- Proposal of merger of the two wholly owned stepdown subsidiaries with a wholly owned subsidiary of the Company.5 Aug 2026
- Amalgamation of two wholly owned subsidiaries of the Company.9 Feb 2026
- Merger of a wholly owned stepdown subsidiary with another wholly owned stepdown subsidiary of the Company2 Jul 2025
- Receipt of NCL Order approving the Scheme of Amalgamation6 May 2024
- Amalgamation/Merger We refer to our letter dated August 12, 2021 informing about the approval of the Scheme of Amalgamation by the Board of Director of the Company, providing for the amalgamation of wholly owned subsidiaries of the Company viz., Auronext Pharma Private and Mviyes Pharma Ventures Private Limited with the Company subject to the requisite statutory I regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).We would like inform you that since there were other restructuring proposals in discussion, this amalgamation was put on hold and now, the Board of Directors of the Company at its meeting held on April 1, 2023 has decided to proceed with the aforesaid Scheme of Amalgamation.1 Apr 2023
6 earlier filings
- Amalgamation/Merger12 Aug 2021
- Amalgamation/Merger29 Apr 2021
- Amalgamation/Merger8 Apr 2021
- Scheme of Arrangement7 Sep 2020
- Scheme of Arrangement28 May 2019
- Hon ble High Court of Judicature of Andhra Pradesh at Hyderabad has sanctioned the Scheme of Arrangement between Aurobindo Pharma Limited and Curepro Parenterals Limited and their respective shareholders and creditors ( Scheme ) under Sections 391 to 394 of the Companies Act, 1956. The Scheme provides for transfer of Injectables Unit IV of Aurobindo to Curepro, its wholly-owned subsidiary, with effect from the Appointed Date April 1, 2014.12 May 2014, a zip file
Aurobindo Pharma share news and announcements
Newest first. Page 1 of 34.
Oct 2026
2 Oct · General Updates
2 Oct · Business
1 Oct · Business
Sep 2026
29 Sep
21 Sep · Analysts
12 Sep · Business
11 Sep · Analysts
11 Sep · Analysts
11 Sep · Analysts
11 Sep · Analysts
11 Sep · Analysts
Aug 2026
25 Aug · Analysts
25 Aug · Analysts
21 Aug · General Updates
14 Aug · Analysts
14 Aug · General Updates
13 Aug · Business
5 Aug · Results
Jul 2026
27 Jul · Board meeting
Jun 2026
25 Jun · Business
19 Jun
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 6 Aug 2026Resultsdown 1.52%−1.5 pts vs Nifty 500market median −0.7% · five sessions +3.3% (+3.6 pts vs Nifty 500) · volume 1.4× usual · delivery −15.9 pts against usual · The announcement
- 22 May 2026Resultsdown 5.38%−5.6 pts vs Nifty 500market median −0.7% · five sessions −7.8% (−8.0 pts vs Nifty 500) · volume 2.4× usual · delivery −17.2 pts against usual · The announcement
- 22 May 2026Board or managers changeddown 5.38%−5.6 pts vs Nifty 500market median 0.0% · five sessions −7.8% (−8.0 pts vs Nifty 500) · volume 2.4× usual · delivery −17.2 pts against usual · The announcement
- 18 May 2026Buybackdown 0.75%−0.4 pts vs Nifty 500market median 0.0% · five sessions −3.2% (−3.7 pts vs Nifty 500) · volume 0.7× usual · delivery +2.9 pts against usual · The announcement
- 22 Apr 2026Buybackup 2.12%+2.3 pts vs Nifty 500market median 0.0% · five sessions +2.2% (+3.4 pts vs Nifty 500) · volume 1.0× usual · delivery +4.0 pts against usual · The announcement
- 6 Nov 2025Resultsdown 0.74%−0.1 pts vs Nifty 500market median −0.7% · five sessions +3.0% (+2.3 pts vs Nifty 500) · volume 1.0× usual · delivery −19.7 pts against usual · The announcement
- 4 Nov 2025Board or managers changeddown 0.82%−0.3 pts vs Nifty 500market median 0.0% · five sessions +0.8% (+1.4 pts vs Nifty 500) · volume 0.7× usual · delivery −3.4 pts against usual · The announcement
- 1 Oct 2025Board or managers changedup 0.19%−0.7 pts vs Nifty 500market median 0.0% · five sessions −1.2% (−2.9 pts vs Nifty 500) · volume 0.7× usual · delivery +10.2 pts against usual · The announcement
- 5 Aug 2025Resultsdown 1.02%−0.7 pts vs Nifty 500market median −0.7% · five sessions −3.4% (−2.4 pts vs Nifty 500) · volume 2.4× usual · delivery −8.5 pts against usual · The announcement
- 5 Aug 2025Dividenddown 1.02%−0.7 pts vs Nifty 500market median 0.0% · five sessions −3.4% (−2.4 pts vs Nifty 500) · volume 2.4× usual · delivery −8.5 pts against usual · The announcement
20 earlier announcements
- 7 Feb 2025Resultsdown 0.01%+0.1 pts vs Nifty 500market median −0.7% · five sessions −1.0% (+2.5 pts vs Nifty 500) · volume 1.4× usual · delivery −17.6 pts against usual · The announcement
- 16 Dec 2024Board or managers changedup 3.00%+3.0 pts vs Nifty 500market median 0.0% · five sessions +2.8% (+7.2 pts vs Nifty 500) · volume 1.1× usual · delivery −7.8 pts against usual · The announcement
- 11 Nov 2024Resultsdown 2.90%−2.7 pts vs Nifty 500market median −0.7% · five sessions −6.9% (−3.6 pts vs Nifty 500) · volume 4.1× usual · delivery −13.1 pts against usual · The announcement
- 26 Aug 2024Buybackup 0.63%0.0 pts vs Nifty 500market median 0.0% · five sessions +2.0% (+0.7 pts vs Nifty 500) · volume 0.4× usual · delivery −25.9 pts against usual · The announcement
- 12 Aug 2024Resultsup 0.83%+0.9 pts vs Nifty 500market median −0.7% · five sessions +4.8% (+3.9 pts vs Nifty 500) · volume 1.6× usual · delivery −5.1 pts against usual · The announcement
- 27 May 2024Resultsdown 3.13%−3.2 pts vs Nifty 500market median −0.7% · five sessions −4.0% (−2.2 pts vs Nifty 500) · volume 2.9× usual · delivery −20.9 pts against usual · The announcement
- 8 Apr 2024Board or managers changeddown 0.31%−0.8 pts vs Nifty 500market median 0.0% · five sessions −3.4% (−2.3 pts vs Nifty 500) · volume 1.1× usual · delivery −2.9 pts against usual · The announcement
- 6 Mar 2024Board or managers changeddown 2.18%−2.2 pts vs Nifty 500market median 0.0% · five sessions −7.2% (−3.6 pts vs Nifty 500) · volume 0.6× usual · delivery −3.5 pts against usual · The announcement
- 12 Feb 2024Dividendup 1.55%+3.0 pts vs Nifty 500market median 0.0% · five sessions +3.1% (+2.1 pts vs Nifty 500) · volume 2.1× usual · delivery −18.7 pts against usual · The announcement
- 12 Feb 2024Board or managers changedup 1.55%+3.0 pts vs Nifty 500market median 0.0% · five sessions +3.1% (+2.1 pts vs Nifty 500) · volume 2.1× usual · delivery −18.7 pts against usual · The announcement
- 7 Feb 2024Dividenddown 1.99%−2.4 pts vs Nifty 500market median 0.0% · five sessions +1.2% (+2.4 pts vs Nifty 500) · volume 2.0× usual · delivery +6.1 pts against usual · The announcement
- 10 Nov 2023Dividendup 3.05%+2.8 pts vs Nifty 500market median 0.0% · five sessions +2.7% (+0.5 pts vs Nifty 500) · volume 3.0× usual · delivery −27.3 pts against usual · The announcement
- 29 May 2023Resultsdown 0.58%−1.1 pts vs Nifty 500market median −0.7% · five sessions +7.7% (+7.0 pts vs Nifty 500) · volume 3.1× usual · delivery −16.4 pts against usual · The announcement
- 10 Feb 2023Dividendup 6.33%+6.4 pts vs Nifty 500market median 0.0% · five sessions +8.8% (+8.5 pts vs Nifty 500) · volume 6.3× usual · delivery −28.7 pts against usual · The announcement
- 14 Nov 2022Resultsdown 0.38%−0.4 pts vs Nifty 500market median −0.7% · five sessions −4.1% (−3.5 pts vs Nifty 500) · volume 4.6× usual · delivery −27.0 pts against usual · The announcement
- 31 May 2022Dividendup 0.50%+0.8 pts vs Nifty 500market median 0.0% · five sessions −1.1% (−0.4 pts vs Nifty 500) · volume 3.3× usual · delivery +13.3 pts against usual · The announcement
- 10 Feb 2022Dividendup 4.32%+3.7 pts vs Nifty 500market median 0.0% · five sessions +5.2% (+6.7 pts vs Nifty 500) · volume 3.8× usual · delivery −11.3 pts against usual · The announcement
- 9 Nov 2021Dividendup 0.74%+0.6 pts vs Nifty 500market median 0.0% · five sessions +3.5% (+3.1 pts vs Nifty 500) · volume 5.7× usual · delivery −21.6 pts against usual · The announcement
- 4 Oct 2021Board or managers changedup 2.07%+1.0 pts vs Nifty 500market median 0.0% · five sessions −0.4% (−2.7 pts vs Nifty 500) · volume 2.4× usual · delivery −11.8 pts against usual · The announcement
- 13 Aug 2021Resultsdown 7.86%−8.5 pts vs Nifty 500market median −0.7% · five sessions −17.6% (−17.4 pts vs Nifty 500) · volume 13.4× usual · delivery −12.1 pts against usual · The announcement
Aurobindo Pharma results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.